Relugolix+ Estradiol + Norethindrone Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 40 mg+ 1 mg + 0.5 mg

Reference Brands: Myfembree (USA)

Category: Women's Health

Myfembree is a once‑daily oral combination medication used in premenopausal women to manage heavy menstrual bleeding due to uterine fibroids and moderate to severe pain from endometriosis. It combines a GnRH antagonist to reduce hormone production with estrogen and progestin to support bone health and endometrial protection, approved in the U.S. by the FDA. Relugolix+ estradiol + norethindrone is available in Tablets and strengths such as 40 mg+ 1 mg + 0.5 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Relugolix+ estradiol + norethindrone is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Relugolix+ estradiol + norethindrone can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Myfembree is a prescription oral medication designed for premenopausal women to manage heavy menstrual bleeding caused by uterine fibroids and to relieve moderate to severe pain associated with endometriosis. It contains a combination of three active ingredients: relugolix, estradiol, and norethindrone acetate. Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces hormone production to control symptoms, while estradiol and norethindrone acetate help maintain bone health and protect the uterus during therapy. The medication is formulated as a once-daily tablet with a fixed dose of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, ensuring consistent symptom control with ease of use. Approved by the U.S. FDA, Myfembree is manufactured through a collaboration between Myovant Sciences and Pfizer. It provides a non-surgical option for women seeking relief from uterine fibroid-related bleeding and endometriosis pain, helping improve quality of life by reducing menstrual blood loss, alleviating pelvic pain, and managing hormonal balance. Myfembree should be used under medical supervision, typically for up to 24 months, due to potential risks associated with long-term hormone therapy.